← All trials
NCT03080415
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2017
- Primary completion
- Sep 15, 2017
- Completion date
- Jun 15, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Yassin Abdelghaffar Charity Center for Liver Disease and ResearchLead sponsor
- Yassin Abdel Ghaffar Charity Center for Liver Disease and ResearchOverall official - principal investigator
- Yassin Abdelghaffar Charity Center for Liver Disease and ResearchReponsible party - principal investigator
- Egyptian Cure Bank NGOCollaborator
- Society of Friends of Liver Patients in the Arab World (SLPAW)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.